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The newly discovered peptide, brain natriuretic factor (BNF), caused a concentration-dependent i crease (up to 400-fold) 
in intracellular cyclic GMP levels in cultured endothelial, smooth muscle and fibroblast cells. The extent of cGMP aug- 
mentation was comparable to that produced by atria1 natriuretic factor (ANF). The activity of the membrane-bound 
guanylate cyclase of different rat tissues and cultured cells was markedly stimulated by the peptide and the addition of 
ATP potentiated the stimulation. As opposed to tissue particulate guanylate cyclase, the enzyme in cell membranes was 
slightly more sensitive to activation by BNF than to stimulation by ANF. On bovine aortic smooth muscle (BASM) 
cells, specific high-affinity binding sites (B,,,u = 398 fmol/lW cells, Kd =0.52 nM) for BNF were observed for which ANF 
could compete with apparently equal affinity. These results suggest hat activation of the cGMP pathway constitutes a 
common mechanism of action for both BNF and ANF. 
Brain natriuretic factor; Atria1 natriuretic factor; cyclic GMP, Guanylate cyclase; Receptor binding 
1. INTRODUCTION 
Many studies have demonstrated that atria1 
natriuretic factor (ANF) plays an important role in 
the regulation of blood pressure, electrolyte 
homeostasis, endocrine and other physiological 
functions [ 11. The effects of ANF may be mediated 
by an increase in cellular cyclic guanosine 
monophosphate (cGMP) levels through the activa- 
tion of particulate guanylate cyclase [2,3]. 
Recently, a new biologically active peptide has 
been discovered in porcine brain [4] which, in addi- 
tion to a potent smooth muscle (chicken rectum) 
relaxing activity, can also produce hypotension, an 
increased diuresis and natriuresis in vivo. This new 
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peptide, called brain natriuretic factor (BNF), 
shows a high degree of amino acid sequence 
homology (70%) to ANF. In order to examine the 
possibility that the biological actions of BNF may 
also be mediated by cGMP, we studied the in- 
fluence of this new peptide on intracellular cGMP 
levels and the activity of guanylate cyclase as well 
as its binding properties in various tissues and 
cultured cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
Synthetic porcine BNF, rat ANF(lOl-126), and atriopeptin I
were obtained from Peninsula Labs (Belmont, CA). 
Radioiodinated peptides were prepared using the iodogen 
method [5], and purified by reversed-phase chromatography. 
Iodogen was purchased from Pierce (Rockford, IL). Rat lung 
fibroblasts (CCL192) were obtained from the American Type 
Cell Collection (Rockville, MD). Bovine aortic smooth muscle 
(BASM) and bovine aortic endothelial (BAE) cells were 
prepared as described [6]. Cells were grown and maintained in 
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Fig. 1. Augmentation of intracellular concentrations of cGMP 
induced by BNF (closed symbols) or ANF (open symbols) in 
bovine aortic endothelial (BAE, squares), rat lung fibroblast 
(RLF, diamonds) and bovine aortic smooth muscle (BASM, 
triangles) cells. Cells were incubated for 5 min with the 
indicated peptide concentrations in the presence of 0.5 mM 
isobutylmethylxanthine. Determination of cellular cGMP 
concentrations was performed as described in section 2. 
culture using the same media and incubation conditions as in 
171. 
2.2. Preparation of membranes from tissues and cultured cells 
Female Sprague-Dawley rats (body wt 250-300 g) were 
decapitated; tissues were obtained and homogenized at 4°C in 
4 vols of 50 mM Tris containing 1 mM EDTA, 1 mM 
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride and 
20 rg/ml aprotinin (pH 7.4). For homogenization of cultured 
cells, this solution also contained 250 mM sucrose. The 
homogenates were centrifuged at 100000 x g for 60 min, par- 
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ticulate fractions being washed twice and resuspended in the 
same buffer. 
2.3. Cellular cGMP determination 
Cells grown to confluence in multiwell plates were washed 
twice with serum-free medium containing 10 mM Hepes, pH 
7.3, and preincubated at 37°C for 10 min with the same buffer 
containing 0.5 mM isobutylmethylxanthine (IBMX). Various 
concentrations of ANF or BNF were added to the medium and 
cultures were incubated for a further 5 min. The medium was 
aspirated and cold 6% trichloroacetic acid was added to the 
plates. The amount of cGMP in the trichloroacetic acid extracts 
was determined by radioimmunoassay as in [6-g]. 
2.4. Guanylate cyclase assay 
The activity of guanylate cyclase in washed particulate frac- 
tions was determined at 37°C in 50 mM Tris-HCl (pH 7.6) con- 
taining 1 mM GTP, 4 mM MgClz, a GTP-regenerating system 
(3.75 mM creatine phosphate, 10 U/ml creatine phos- 
phokinase), and 0.5 mM IBMX. The reaction was stopped by 
the addition of ice-cold sodium acetate buffer (50 mM, pH 4.0) 
followed by immersion for 3 min in a boiling water bath. cGMP 
generated was quantified by radioimmunoassay. 
2.5. Binding studies 
Confluent cells were washed twice with serum-free Dulbec- 
co’s modified Eagle’s medium and then incubated for 20 min at 
37°C with medium containing 10 mM Hepes, pH 7.3, 1 mg/ml 
bovine serum albumin and the indicated concentrations of ‘251- 
BNF or ‘?-ANF (spec. act. 1600-1800 Ci/mmol). Following 
5 washing steps with Hank’s balanced salt solution containing 
1 mg/ml bovine serum albumin, the cells were solubilized with 
1 M NaOH and the radioactivity was determined. Non-specific 
binding was determined by incubating parallel culture dishes 
with ‘251-labeled peptides in the presence of 1 PM unlabeled 
peptides. All values presented are the means of duplicate or 
triplicate incubations from representative experiments that were 
performed two or three times. 
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Fig.2. Time course of cGMP formation by rat lung (A) and bovine aortic endothelial cell (B) membrane-bound guanylate cyclase. 
Enzyme activity was monitored at 37“C in the absence (x) or presence of 1 pM each of BNF (closed symbols), or ANF (open symbols), 
as described in section 2. 
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Fig.3. Stimulation of rat lung particulate guanylate cyclase 
activity by BNF (closed symbols) in comparison to ANF (open 
symbols). Peptides were added to the reaction mixtures for the 
enzyme assay at the indicated concentrations. Determination of 
enzyme activity was performed at 37°C in the absence 
(diamonds) or presence (squares) of 0.1 mM ATP. 
3. RESULTS 
The effect of BNF on the accumulation of in- 
tracellular cGMP was investigated using bovine 
aortic smooth muscle (BASM), bovine aortic en- 
dothelial (BAE), and rat lung fibroblast (RLF) 
cells. As shown in fig.1, incubation with BNF 
elevated the cGMP concentration in all cell lines in 
a dose-dependent fashion. The maximal increase in 
intracellular cGMP concentrations by BNF was 
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found to be gimilar in BAE and RLF cells (-360- 
and 400-fold, respectively), while a lower response 
(-50-fold) was observed in BASM cells. In the lat- 
ter cells, maximum stimulation apparently could 
not be reached up to the highest concentration of 
peptide examined. The effects of BNF and ANF on 
cGMP accumulation were comparable in each of 
the cell lines examined (fig.1). 
In order to examine and compare the effects of 
BNF and ANF on particulate guanylate cyclase ac- 
tivity, membrane fractions were prepared from rat 
lung and BAE cells. In these preparations, the time 
course of guanylate cyclase activity was in- 
vestigated in the presence of 1 pM BNF or ANF 
(fig.2). The enzymatic activity in the presence of 
BNF was significantly higher than in control in- 
cubations. Compared to the effect of ANF, the 
stimulation of enzyme activity by BNF was less 
marked in the lung membranes, whereas greater 
stimulation of guanylate cyclase by BNF was 
observed in the preparation derived from en- 
dothelial cells. 
Fig.3 depicts the concentration dependence for 
stimulation of rat lung particulate guanylate 
cyclase activity by BNF and ANF. Both peptides 
activated the enzyme about 2.5-fold. However, the 
concentration required for half-maximal activa- 
tion was about one order of magnitude higher for 
BNF (EC50 100-200 nM) than that observed for 
ANF (EC50 lo-20 nM). The stimulation of 
membrane-bound guanylate cyclase activities by 
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Fig.4. Activation of guanylate cyclase in rat tissue particulate fractions and BAE cell membranes by BNF (1 PM, closed columns) as 
compared to ANF (open columns). Basal enzyme activity in the membrane preparations is represented by the hatched columns. (A) 
Guanylate cyclase activity was determined as described in section 2; (B) enzyme activities after addition of 0.1 mM ATP. 
127 
Volume 232, number 1 FEBS LETTERS May 1988 
either BNF or ANF was markedly enhanced in the 
presence of ATP (0.1 mM) without a shift in the 
EGO values. This has also been reported previous- 
ly [lo] for the stimulation of guanylate cyclase 
from other tissues by ANF. 
The ability of BNF to stimulate the activity of 
particulate guanylate cyclase was further in- 
vestigated in membrane preparations from a varie- 
ty of rat tissues. As shown in fig.4, 1 PM BNF 
stimulated particulate guanylate cyclase activity in 
all tissues examined. The highest specific activity 
of the enzyme in tissue particulate fractions upon 
addition of BNF was observed in lung membranes, 
while the highest relative stimulation compared to 
basal activity was found in liver (5.2-fold) and 
kidney (4.8-fold) particulate fractions. Compared 
to the effects of 1 ,uM ANF on enzyme activity in 
these membrane preparations (fig.4), the extent of 
activation by BNF was nearly identical to that 
caused by ANF. For the particulate guanylate 
cyclase from cultured BAE cells, however, BNF 
was more effective than ANF. 
The characteristics of BNF receptors were ex- 
amined using BASM cells. FigSA demonstrates 
that a specific and saturable high-affinity binding 
of lz51-BNF could be observed. Analysis of the 
binding data according to Scatchard (figSA, inset) 
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resulted in a linear plot, suggesting the presence of 
a single class of receptors with an apparent 
equilibrium dissociation constant (&) of 0.52 nM 
and a maximum binding of 398 fmol/106 cells. As 
shown in fig.SB, unlabeled BNF as well as unla- 
beled ANF could compete with very similar affini- 
ty for the binding of radioactive BNF to these 
receptors while the truncated ANF analog, atrio- 
peptin I, is slightly less potent. In the reverse ex- 
periment, unlabeled BNF could also displace 
lz51-ANF from its binding sites on BASM cells. 
4. DISCUSSION 
At present, there is accumulating evidence that 
the biological functions of ANF are not restricted 
to peripheral tissues but are also of considerable 
importance in the central nervous system (CNS) 
[l 11. The presence of ANF-like peptides has been 
demonstrated in hypothalamic regions [12]; 
however, their molecular structures apparently dif- 
fer from the peripherally prevalent form in that 
three or four N-terminal amino acids are deleted 
[13]. Furthermore, an additional peptide, the 
recently identified BNF [4], is structurally related 
to ANF but has 8 amino acid substitutions and one 
insertion. This peptide family may contribute to 
Fig.5. Characterization of BNF receptors on bovine aortic smooth muscle cells. (A) Equilibrium binding isotherm obtained after 
incubation of cells with increasing concentrations of iz51-BNF for 30 min. Experimental conditions for determination of specific 
(closed squares) and nonspecific (open squares) binding are described in section 2. (Inset) Scatchard plot of the specific binding. (B) 
Displacement of radiolabeled BNF (closed symbols) from binding sites by unlabeled BNF (squares), or ANF (triangles). Open symbols 
represent competition of unlabeled BNF or ANF to the binding of “‘1-ANF. Additionally, the effect of different concentrations of 
AP-I on the binding of BNF is shown (X). ‘251-labeled peptides were used at 0.27 nM. 
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the central as well as the peripheral effects of these 
new hormones. 
The present results show that BNF exerts some 
of its actions via an elevation of intracellular 
cGMP levels. This second messenger molecule can 
be produced by two isoforms of the enzyme, 
guanylate cyclase [ 141. Only the particulate isoen- 
zyme has been shown to be activated by the atria1 
peptide [2], and our experiments demonstrate that 
in tissues as well as in cell cultures, the brain pep- 
tide (BNF) also stimulates this enzyme. Surprising- 
ly, no major differences in tissue specificity or 
potency can be observed for either peptide which 
suggests that the mechanism of guanylate cyclase 
activation is similar if not identical for BNF and 
ANF. 
In brain, binding sites have been found which 
are believed to be specific for ANF [15]. However, 
the results of our investigations demonstrate that 
BNF has the ability to compete effectively for ANF 
binding in cultured cells; therefore, it is likely that 
the ANF receptors in the CNS can be occupied by 
BNF as well. Receptors for ANF can be classified 
into two subtypes, designated ANF-Rl and -R2, 
respectively, which may be distinguished by their 
molecular and functional characteristics [ 161. Only 
the Rl receptor is coupled to the membrane-bound 
guanylate cyclase, while unique functions of the 
much more abundant R2 receptor remain 
unknown. The activation of tissue and cellular par- 
ticulate guanylate cyclase by BNF demonstrated in 
this report shows that this peptide binds to the Rl 
receptor, while the direct binding experiments us- 
ing radiolabeled BNF provide evidence for the oc- 
cupation of the more abundant R2 receptor as 
well. Thus, BNF, as is the case with most ANF 
analogues, does not bind selectively to one of the 
two ANF receptors. 
In conclusion, our results support the concept of 
a new class of biologically active peptides that may 
be part of a broader family of related peptides. 
The common feature of these peptides is the 
molecular mechanism underlying their action, i.e. 
the occupation of receptors coupled to the activa- 
tion of membrane-bound guanylate cyclase and, 
subsequently, the elevation of intracellular cGMP. 
While investigations of cGMP metabolism may 
facilitate the discovery of other related peptides, 
this new class of peptide hormones should permit 
us to evaluate the biological functions of cGMP. 
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